Citations 1
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Kumar, Shaji , Gasparetto, Cristina , Vij, Ravi , Pegourié, Brigitte, Benboubker, Lofti, Amiot, Martine , Moreau, Philippe , Punnoose, Elizabeth A. , Alzate, Stefanie, Dunbar, Martin, Xu, Tu , Agarwal, Suresh , Enschede, Sari H., Maciag, Paulo , Verdugo, Maria, Touzeau, Cyrille , Mıkhael, Joseph , Moreau, Philippe , Touzeau, Cyrille , Kaufman, Jonathan L. , Benboubker, Lotfi , Facon, Thierry T.F. , Leverson, Joel D. , Ross, Jeremy A.
Blood | October 10, 2017 | Volume: 130 | Issue: 22 | Pages: 2401-2409
Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).